Journey Medical Corporation,(DERM) a leading healthcare company, has released its unaudited condensed consolidated financial statements for the first quarter ended March 31, 2023. The report reveals a net loss of $10.1 million for the quarter, reflecting a challenging period for the company. Additionally, the revenue for the quarter stood at $12.2 million, showing a decline compared to the same period last year. Let's delve into the details of Journey Medical Corporation's financial performance.
Journey Medical Corporation's unaudited condensed consolidated balance sheets indicate that the company's total assets amounted to $95.9 million as of March 31, 2023, compared to $105.2 million at the end of 2022. The company's current assets decreased to $60.7 million from $77.7 million, primarily driven by reduced cash and cash equivalents, accounts receivable, and inventory. Meanwhile, the company's intangible assets remained relatively stable at $26.1 million.
The unaudited condensed consolidated balance sheets also highlight the company's liabilities and stockholders' equity. Journey Medical Corporation's total liabilities as of March 31, 2023, amounted to $88.4 million, slightly higher than the $88.2 million reported at the end of 2022. The company's current liabilities increased to $76.9 million, primarily due to higher accounts payable and accrued expenses. On the other hand, the company's stockholders' equity decreased to $7.5 million from $17.0 million, reflecting the net loss incurred during the quarter.
Journey Medical Corporation's unaudited condensed consolidated statements of operations reveal that the company generated $12.2 million in revenue during the first quarter of 2023. This represents a decline from the $23.3 million reported in the same period last year. The decrease in revenue can be attributed to lower product revenue, which amounted to $12.2 million, compared to $20.8 million in the previous year. Other revenue contributed a nominal amount of $48, contrasting with $2.5 million in the first quarter of 2022.
The company's operating expenses for the quarter totaled $21.8 million, slightly lower than the $24.2 million reported in the previous year. These expenses comprised cost of goods sold, research and development, and selling, general, and administrative costs. Journey Medical Corporation recorded a loss from operations of $9.6 million, a significant increase compared to the loss of $0.9 million in the same period last year.
During the first quarter of 2023, Journey Medical Corporation reported a net loss of $10.1 million. This represents a substantial increase from the net loss of $1.4 million incurred in the first quarter of 2022. The company's loss before income taxes amounted to $10.1 million, compared to $1.3 million in the previous year. The net loss per common share for the quarter was $0.57, based on a weighted average number of 17.8 million common shares outstanding.
Journey Medical Corporation's financial statements for the first quarter of 2023 reflect a challenging period for the company, characterized by a decline in revenue and an increased net loss. The company faced headwinds in its product revenue, contributing to the overall decrease in revenue. As the company moves forward, it will need to implement strategic measures to enhance its financial performance and address the factors that impacted its results. With a focus on improving revenue generation and controlling operating expenses, Journey Medical Corporation aims to regain stability and profitability in the coming quarters.